Compare RHP & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RHP | GKOS |
|---|---|---|
| Founded | 1991 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 6.3B |
| IPO Year | 1991 | 2015 |
| Metric | RHP | GKOS |
|---|---|---|
| Price | $94.72 | $120.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 14 |
| Target Price | $109.33 | ★ $127.71 |
| AVG Volume (30 Days) | 447.3K | ★ 647.8K |
| Earning Date | 02-23-2026 | 02-17-2026 |
| Dividend Yield | ★ 5.07% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.77 | N/A |
| Revenue | ★ $2,486,871,000.00 | $469,820,000.00 |
| Revenue This Year | $8.66 | $31.33 |
| Revenue Next Year | $7.67 | $24.01 |
| P/E Ratio | $25.13 | ★ N/A |
| Revenue Growth | 6.48 | ★ 30.38 |
| 52 Week Low | $76.27 | $73.16 |
| 52 Week High | $108.42 | $163.71 |
| Indicator | RHP | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 49.61 | 64.15 |
| Support Level | $92.53 | $93.96 |
| Resistance Level | $96.09 | $115.00 |
| Average True Range (ATR) | 2.17 | 4.48 |
| MACD | -0.19 | -0.42 |
| Stochastic Oscillator | 54.57 | 94.40 |
Ryman Hospitality Properties Inc is a lodging and hospitality real estate investment trust that specializes in upscale convention center resorts and country music entertainment experiences. Its core holdings are Gaylord Opryland Resort & Convention Center; Gaylord Palms Resort & Convention Center; Gaylord Texan Resort & Convention Center; Gaylord National Resort & Convention Center; and Gaylord Rockies Resort & Convention Center. The company has three business segments: Hospitality, which includes Gaylord Hotels properties, the Inn at Opryland, and the AC Hotel, Entertainment which includes the entertainment and media assets comprising OEG, and Corporate and Other, which includes corporate expenses. It derives the vast majority of its revenue from its Hospitality segment.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.